Wall Street analyst estimates for AC Immune S.A. (ACIU): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 0.89 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.22 | ||
| 2026-08-05 | $0.03 | $-0.10 | +128.7% |
| 2026-04-30 | $-0.19 | $-0.20 | +5.0% |
| 2026-03-13 | $-0.18 | $-0.19 | +5.3% |
| 2025-11-04 | $-0.20 | $-0.22 | +9.1% |
| 2025-08-05 | $-0.25 | $-0.20 | -25.0% |
| 2025-04-30 | $-0.21 | $-0.22 | +4.5% |
| 2025-03-13 | $-0.18 | $-0.21 | +14.3% |
Valuation Ratios
| Price / Book | 6.42 |
| EV / EBITDA | -5.05 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.2M | $20.3M | $7.2M | $110.5M | $15.4M | 0 | $3.9M | $14.8M | $27.3M | $3.6M |
| Cost of Revenue | $25.8M | $32.7M | $44.3M | $50.4M | $59.5M | 0 | 0 | $54.6M | $62.6M | 0 |
| Gross Profit | -$2.6M | -$12.4M | -$37.1M | $60.0M | -$44.1M | 0 | $3.9M | -$39.8M | -$35.3M | $3.6M |
| Research & Development | $25.8M | $32.7M | $44.3M | $50.4M | $59.5M | $62.3M | $60.3M | $54.6M | $62.6M | $56.4M |
| Selling, General & Admin | $4.7M | $6.3M | $7.6M | $16.1M | $18.6M | $10.9M | $9.6M | $10.6M | $11.4M | $11.7M |
| Operating Expenses | $33.7M | $42.8M | $56.7M | $15.5M | $17.2M | $79.0M | $74.8M | $13.8M | $17.1M | $72.4M |
| Operating Income | -$10.5M | -$22.5M | -$49.5M | $44.5M | -$61.3M | -$79.0M | -$70.8M | -$53.6M | -$52.4M | -$68.9M |
| EBITDA | -$6.8M | -$22.5M | -$49.7M | $45.8M | -$59.7M | -$70.0M | -$68.0M | -$51.8M | -$48.6M | -$67.8M |
| Interest Expense | $256000 | $147000 | $334000 | $1.9M | $184000 | $581000 | $355000 | $176000 | $133000 | $191000 |
| Pre-tax Income | -$7.1M | -$26.4M | -$51.0M | $45.4M | -$61.9M | -$73.0M | -$70.7M | -$54.2M | -$50.9M | -$70.4M |
| Income Tax | 0 | $147000 | 0 | 0 | 0 | $3000 | $13000 | $10000 | $3000 | 0 |
| Net Income | -$7.1M | -$26.4M | -$51.0M | $45.4M | -$61.9M | -$73.0M | -$70.8M | -$54.2M | -$50.9M | -$70.4M |
| EPS | $-0.14 | $-0.46 | $-0.82 | $0.64 | $-0.86 | $-0.97 | $-0.85 | $-0.64 | $-0.51 | $-0.70 |
| EPS (Diluted) | $-0.14 | $-0.46 | $-0.82 | $0.64 | $-0.86 | $-0.97 | $-0.85 | $-0.64 | $-0.51 | $-0.70 |
| Shares Outstanding (Diluted) | $50.1M | $57.4M | $61.8M | $71.1M | $71.9M | $75.0M | $83.6M | $84.7M | $99.7M | $100.8M |
Price
| Price | $2.65 |
| Market Cap | $270M |
| Exchange | NASDAQ |
| Country | CH |
Related companies: ALDX · AMRN · ANNX · ANRO · CLLS · CTNM · DRTS
Explore sector: Healthcare · Biotechnology
More sections of ACIU: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks